Short Interest in VanEck Biotech ETF (NASDAQ:BBH) Increases By 107.2%

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 14,260 shares, a growth of 107.2% from the January 29th total of 6,883 shares. Based on an average trading volume of 7,038 shares, the short-interest ratio is presently 2.0 days. Approximately 0.7% of the shares of the company are short sold. Approximately 0.7% of the shares of the company are short sold. Based on an average trading volume of 7,038 shares, the short-interest ratio is presently 2.0 days.

VanEck Biotech ETF Price Performance

NASDAQ:BBH opened at $197.98 on Friday. The business has a fifty day simple moving average of $194.80 and a two-hundred day simple moving average of $183.53. VanEck Biotech ETF has a 1 year low of $135.34 and a 1 year high of $202.91.

VanEck Biotech ETF Dividend Announcement

The company also recently disclosed an annual dividend, which was paid on Friday, December 26th. Investors of record on Monday, December 22nd were paid a $0.9565 dividend. This represents a yield of 50.0%. The ex-dividend date was Monday, December 22nd.

Hedge Funds Weigh In On VanEck Biotech ETF

Several large investors have recently modified their holdings of BBH. Farther Finance Advisors LLC lifted its stake in shares of VanEck Biotech ETF by 66.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 201 shares of the company’s stock valued at $33,000 after buying an additional 80 shares in the last quarter. Caldwell Trust Co bought a new stake in VanEck Biotech ETF during the 2nd quarter valued at $34,000. Empowered Funds LLC purchased a new stake in shares of VanEck Biotech ETF during the fourth quarter worth $38,000. Flagship Harbor Advisors LLC bought a new position in shares of VanEck Biotech ETF in the fourth quarter worth $47,000. Finally, Allworth Financial LP grew its position in shares of VanEck Biotech ETF by 255.0% in the fourth quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after purchasing an additional 306 shares in the last quarter. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.